Abstract
This case highlights the potential consequences that false-positive (FP) urine drug screen (UDS) results can have on patient care and reinforces the need to confirm preliminary screen results with a direct method, such as liquid chromatography–tandem mass spectrometry (LC-MS/MS). Rather than act on the unexpected results, the transplant team appropriately consulted the laboratory and confirmatory testing was performed. Neither fentanyl or norfentanyl were detected on the LC-MS/MS confirmation assay, meaning the immunoassay screen result was a FP.